---
schema_version: "secwatch.filing_event.v1"
accession: "0001274737-23-000074"
form_type: "8-K"
ticker: "XGN"
cik: "0001274737"
company_name: "EXAGEN INC."
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:04:02.614395+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.3
calibrated_materiality_score: 0.3
confidence: "high"
source: SEC EDGAR
---

# Exagen appoints Paul Kim to board of directors; Kim is CFO of Fulgent Genetics

## Summary
- Paul Kim appointed to Exagen board as Class II director effective July 24, 2023.
- Kim also appointed to Audit Committee and Compensation Committee.
- Kim has served as CFO of Fulgent Genetics (FLGT) since 2016; previously CFO of Cogent, Inc.
- Kim received option to purchase 15,000 shares vesting over 3 years; standard director compensation.

## SEC filing metadata
- accession: 0001274737-23-000074
- form_type: 8-K
- ticker: XGN
- cik: 0001274737
- company_name: EXAGEN INC.
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.3
- calibrated_materiality_score: 0.3
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000074/0001274737-23-000074-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000074/exdx-20230724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001274737-23-000074
- JSON: https://secwatch.observer/filing/0001274737-23-000074.json
- Plain text: https://secwatch.observer/filing/0001274737-23-000074.txt

## Key facts
- Executive change
  Paul Kim was appointed as Class II Director at EXAGEN INC..
  - Action: appointed
  - Role: Class II Director
  source text: the Board appointed Paul Kim to serve as a Class II director, with an initial term expiring at the Company’s 2024 annual meeting of stockholders, filling the vacancy on the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1274737/000127473723000074/0001274737-23-000074-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.